- Home
- ETNB vs SPRY Comparison
ETNB vs SPRY Comparison
Compare ETNB & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- SPRY
- Stock Information
- Founded
- ETNB 2018
- SPRY 2015
- Country
- ETNB United States
- SPRY United States
- Employees
- ETNB N/A
- SPRY N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- ETNB Health Care
- SPRY Health Care
- Exchange
- ETNB Nasdaq
- SPRY Nasdaq
- Market Cap
- ETNB 1.5B
- SPRY 1.4B
- IPO Year
- ETNB 2019
- SPRY N/A
- Fundamental
- Price
- ETNB $10.08
- SPRY $15.69
- Analyst Decision
- ETNB Strong Buy
- SPRY Strong Buy
- Analyst Count
- ETNB 8
- SPRY 4
- Target Price
- ETNB $26.43
- SPRY $28.75
- AVG Volume (30 Days)
- ETNB 2.2M
- SPRY 1.2M
- Earning Date
- ETNB 08-04-2025
- SPRY 08-05-2025
- Dividend Yield
- ETNB N/A
- SPRY N/A
- EPS Growth
- ETNB N/A
- SPRY N/A
- EPS
- ETNB N/A
- SPRY N/A
- Revenue
- ETNB N/A
- SPRY $97,122,000.00
- Revenue This Year
- ETNB N/A
- SPRY N/A
- Revenue Next Year
- ETNB N/A
- SPRY $140.40
- P/E Ratio
- ETNB N/A
- SPRY N/A
- Revenue Growth
- ETNB N/A
- SPRY 971120.00
- 52 Week Low
- ETNB $4.16
- SPRY $7.55
- 52 Week High
- ETNB $11.84
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- ETNB 57.88
- SPRY 60.81
- Support Level
- ETNB $9.66
- SPRY $14.77
- Resistance Level
- ETNB $10.58
- SPRY $16.23
- Average True Range (ATR)
- ETNB 0.55
- SPRY 0.73
- MACD
- ETNB -0.09
- SPRY 0.12
- Stochastic Oscillator
- ETNB 58.39
- SPRY 84.68
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.